Latest News
Report: ChemoCentryx’s CCX168 can meet major unmet needs in vasculitis patients
CCX 168, a small molecule being developed by US-based, clinical-stage biopharmaceutical company ChemoCentryx, is a potential treatment for a number of major unmet needs in vasculitis patients...
M&As this week: Shanghai Fosun Pharmaceutical, Pfizer and Luminex
Shanghai Fosun Pharmaceutical, a biopharmaceutical and healthcare company, plans to develop its drug manufacturing and R&D capacity by acquiring Gland Pharma, an Indian pharmaceutical...
Report: Global market for Huntington’s disease therapeutic to record 25.6% CAGR up to 2024
The Huntington’s disease market is projected to grow at a compound annual growth rate (CAGR) of 25.6% to reach $2.6bn by 2024, says a new GlobalData report. The $252.6m market is anticipated...
Deals this week: Agios Pharma, Sanofi Genzyme and Teleflex
Agios Pharma and Celgene Corporation have entered a co-development agreement to jointly develop and commercialise therapies for the treatment of metabolic immune...
Report: Outlook for cellular immunotherapy in immuno-oncology market positive in the long-term
Cellular immunotherapy is poised to grow significantly in the future, rendering a positive effect on the immuno-oncology market, says a GlobalData...
M&As this week: Incyte, Aptuit
Incyte has announced it will acquire ARIAD Pharmaceuticals for a sale consideration of $140m, to expand its medical and commercial market in Europe and develop its clinical development and...
Deals of the week: Immune Design, Epizyme, Chiesi farmaceutici
Immune Design has entered a clinical trial agreement with Gritstone Oncology to further develop neoantigen cancer...
Report: Renal denervation market to surge at a compound annual growth rate of 44.2%
The market for renal denervation is expected to grow at a compound annual growth rate of 44.2% by 2022, says a GlobalData...
M&As this week: Precision for Medicine, Veristat and Ergomed
Precision for Medicine, a subsidiary of Precision Medicine Group, has acquired Applied Immunology to expand its laboratory services in cell-based and immunoassays and to provide...
Deals of the week: Transplant Genomics, Prosetta Biosciences, Orchard Therapeutics
Transplant Genomics and Astellas Pharma have entered a partnership to further develop laboratory services and clinical trials for renal transplant...
Report: Renal cell carcinoma to be a $3.6bn market by 2023
A GlobalData report has revealed that the major markets of the US, the UK, France, Germany, Italy, Spain, Japan and China will lead the growth in renal cell carcinoma (RCC) from $2.1bn in 2013...
M&As this week: West Pharmaceuticals, DNA2.0
West Pharmaceuticals has invested in Nanopass technologies to access its expertise in intradermal drug delivery...
Deals this week: Evotec, Recursion Pharmaceuticals, Immunicum AB, Vernalis, Fonds De Solidarite FTQ
Evotec has entered a co-development agreement with Ex Scientia to tackle the challenges of complex biology by developing immune-oncology...
The week in M&A: Chongqing Sansheng, Recipharm
Chongqing Sansheng has announced that it will acquire a 100% interest in Liaoyuan City Baikang Pharmaceutical for a consideration of $40.13m....
Deals this week: Heptares Therapeutics, AC Immune, R-Biopharma, BioMotiv, Recipharm
Heptares Therapeutics and Kymab Limited have entered a partnership to jointly undertake an antibody discovery and development programme using the former’s StaR platform and the latter’s Kymouse....
Report: Immuno-oncology market to witness double-digit growth
Long and durable tumour responses and lesser side-effects are expected to make immuno-oncology drugs a preferred choice of treatment, helping the sector to grow to $34bn by 2024, says a report...
Deals this week: Cantabio Pharma, Lupin, Shanghai Fosun Pharma, Intellia Therapeutics
Cantabio Pharma has signed a drug discovery agreement with NovAliX S.A.S for the development of a new therapy for treatment of Alzheimer’s disease....
Deals this week: NantBioscience and Nantkwest, Cutis Pharma, Sorrento Therapeutics
NantBioscience and Nantkwest have entered a cooperative research and development agreement (CRADA) with National Cancer Institute (NCI) and National Institute of Health (NIH) to develop...
Cleveland Clinic announces first uterus transplant in US fails
Ohio-based Cleveland Clinic has revealed that the first uterus transplant in the US has failed, and that doctors had removed the organ after the patient suffered...
Xencor begins Phase II trials of XmAb5871 for IgG4-related disease and SLE
US-based Xencor has started a Phase II trial of its drug candidate XmAb5871 in patients with IgG4-related disease (IgG4-RD), as well as patients with systemic lupus erythematosus...
New study finds 60% of academic clinical trial results not shared
A new study conducted by Yale School of Medicine researchers has revealed that about 60% of academic clinical trial results were not being shared after...
